

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
13381

In Re Application Of: William Delaney, et al.


Serial No.  
09/781,891

Filing Date  
February 2, 2001

Examiner  
Unassigned

Group Art Unit  
1645

Title:  
AN ASSAY



RECEIVED  
OCT 09 2001  
TECH CENTER 1600/2900

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:
1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
13381

In Re Application Of: William Delaney, et al.

Serial No.  
09/781,891

Filing Date  
February 2, 2001

Examiner  
Unassigned

Group Art Unit  
1645

Title:  
AN ASSAY



RECEIVED  
OCT 09 2001  
TECH CENTER 1600/2900

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on October 1, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Janet Grossman*  
Signature of Person Mailing Correspondence

Janet Grossman  
Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

*Frank S. DiGiglio*  
Signature

Dated: October 1, 2001

Frank S. DiGiglio  
Registration No. 31,346  
SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

FSD/sf

CC:



#6      GAU 1645

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** William Delaney, et al.

**Examiner:** Unassigned

**Serial No:** 09/781,891

**Art Unit:** 1645

**Filed:** February 2, 2001

**Docket:** 13381

**For:** AN ASSAY

**Dated:** October 1, 2001

Assistant Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Delaney IV, et al., (1999) "Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of (-)-B-2', 3'- Dideoxy-3'- Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA", Antimicrobial Agents and Chemotherapy 43(8):2017-2026;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on October 1, 2001.

Dated: October 1, 2001

*Janet Grossman*  
Janet Grossman


2. Harrison, et al., (1991) "Independent Emergence of a Vaccine-Induced Escape Mutant of Hepatitis B Virus", Journal of Hepatology **13**, (4) S105-S107;
3. Fujii, et al. (1992) "Gly<sup>145</sup> To Arg Substitution in HBs Antigen of Immune Escape Mutant of Hepatitis B Virus", Biochemical and Biophysical Research Communications, **184** (3) :1152-1157;
4. Delaney IV, et al., (1998) "Hepatitis B Virus Replication in Human HepG2 Cells Mediated by Hepatitis B Virus Recombinant Baculovirus", Journal of Hepatology **28** :1134-1146;
5. McMahon, et al. (1992) "Genetic Alterations in the Gene Encoding the Major HbsAg: DNA and Immunological Analysis of Recurrent HbsAg Derived from Monoclonal Antibody-Treated Liver Transplant Patients", Journal of Hepatology **15** :757-766;
6. Okamoto, et al. (1992) "Mutations within the S Gene of Hepatitis B Virus Transmitted from Mothers to Babies Immunized with Hepatitis B Immune Globulin and Vaccine", Pediatric Research **32** (3) :264-268;
7. Carman, et al., (1990) "Vaccine-Induced Escape Mutant of Hepatitis B Virus", The Lancet **336** :325-329;
8. Carman, et al. (1992) "Genetic Variation in Hepatitis B Virus", The American Gastroenterological Association **102** :711-719;
9. Gerlich, et al. (1991) "Functions of Hepatitis B Virus Proteins and Virus Assembly", Viral Hepatitis and Liver Disease, F.B. Hollinger, et al. Eds., Williams-Wilkens, Baltimore, MD :121-134;
10. Tiollais, et al. (1985) "The Hepatitis B Virus", Nature **317** : 489-495;

11. Stuyver, et al. (2000) "A New Genotype of Hepatitis B Virus: Complete Genome and Phylogenetic Relatedness", Journal of General Virology 81 :67-74;
12. Ryder, et al. (1984) "Screening for Hepatitis B Virus Markers is not Justified in West African Transfusion Centres", The Lancet :449-452;
13. Norder, et al. (1993) "Genetic Relatedness of Hepatitis B Viral Strains of Diverse Geographical Origin and Natural Variations in the Primary Structure of the Surface Antigen", Journal of General Virology 74 :1341-1348, and
14. Beasley, et al. (1981) "Hepatocellular Carcinoma and Hepatitis B Virus", The Lancet :1129-1133.

Applicants are submitting copies of the above-cited references.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Frank S. DiGiglio  
Registration No. 31,346

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

FSD/sf